Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Nov. 12, 2014, 173 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $57.29 to $21,893,760.00.

Highlighted Stocks Traded by Insiders:

Cognizant Technology Solutions (CTSH) - FREE Research Report

Krishnaswamy Venkat, who is EVP, Pres Healthcare & Life Sc at Cognizant Technology Solutions, sold 4,066 shares at $53.00 on Nov. 12, 2014. Following this transaction, the EVP, Pres Healthcare & Life Sc owned 4,029 shares meaning that the stake was reduced by 50.23% with the 4,066-share transaction.

The shares most recently traded at $53.50, up $0.50, or 0.93% since the insider transaction. Historical insider transactions for Cognizant Technology Solutions go as follows:

  • 4-Week # shares sold: 94,907
  • 12-Week # shares sold: 94,907
  • 24-Week # shares bought: 7,500
  • 24-Week # shares sold: 141,514

The average volume for Cognizant Technology Solutions has been 5.3 million shares per day over the past 30 days. Cognizant Technology Solutions has a market cap of $32.4 billion and is part of the technology sector and computer software & services industry. Shares are up 5.45% year-to-date as of the close of trading on Wednesday.

Cognizant Technology Solutions Corporation provides information technology (IT), consulting, and business process services worldwide. The company operates in four segments: Financial Services, Healthcare, Manufacturing/Retail/Logistics, and Other. The company has a P/E ratio of 23.1. Currently, there are 10 analysts who rate Cognizant Technology Solutions a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CTSH - FREE

TheStreet Quant Ratings

rates Cognizant Technology Solutions as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, solid stock price performance and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full

Cognizant Technology Solutions Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Prospect Capital Corporation (PSEC) - FREE Research Report

Eliasek M Grier, who is Chief Operating Officer at Prospect Capital Corporation, bought 5,000 shares at $9.56 on Nov. 12, 2014. Following this transaction, the Chief Operating Officer owned 197,196 shares meaning that the stake was boosted by 2.6% with the 5,000-share transaction.

Barry John F, who is Chief Executive Officer at Prospect Capital Corporation, bought 110,000 shares at $9.57 on Nov. 12, 2014. Following this transaction, the Chief Executive Officer owned 4.5 million shares meaning that the stake was boosted by 2.49% with the 110,000-share transaction.

Stark Eugene S, who is Director at Prospect Capital Corporation, bought 1,512 shares at $9.40 on Nov. 12, 2014. Following this transaction, the Director owned 21,000 shares meaning that the stake was boosted by 7.76% with the 1,512-share transaction.

The shares most recently traded at $9.69, up $0.29, or 2.99% since the insider transaction. Historical insider transactions for Prospect Capital Corporation go as follows:

  • 4-Week # shares bought: 105,000
  • 12-Week # shares bought: 156,300
  • 24-Week # shares bought: 411,300

The average volume for Prospect Capital Corporation has been 4.3 million shares per day over the past 30 days. Prospect Capital Corporation has a market cap of $3.4 billion and is part of the financial sector and financial services industry. Shares are down 13.64% year-to-date as of the close of trading on Wednesday.

Prospect Capital Corporation is a business development company. The stock currently has a dividend yield of 13.83%. The company has a P/E ratio of 9.7. Currently, there are 6 analysts who rate Prospect Capital Corporation a buy, no analysts rate it a sell, and 5 rate it a hold.

TST Recommends

Exclusive Offer: Get the latest Stock Analysis on PSEC - FREE

TheStreet Quant Ratings

rates Prospect Capital Corporation as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Prospect Capital Corporation Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Covidien (COV) - FREE Research Report

Clemmer James C, who is Senior Vice President at Covidien, sold 3,464 shares at $92.48 on Nov. 12, 2014. Following this transaction, the Senior Vice President owned 49,190 shares meaning that the stake was reduced by 6.58% with the 3,464-share transaction.

The shares most recently traded at $93.87, up $1.39, or 1.48% since the insider transaction. Historical insider transactions for Covidien go as follows:

  • 4-Week # shares bought: 2,447
  • 4-Week # shares sold: 4,000
  • 12-Week # shares bought: 3,647
  • 12-Week # shares sold: 4,000
  • 24-Week # shares bought: 10,597
  • 24-Week # shares sold: 4,000

The average volume for Covidien has been 4.9 million shares per day over the past 30 days. Covidien has a market cap of $42.3 billion and is part of the health care sector and health services industry. Shares are up 36.39% year-to-date as of the close of trading on Wednesday.

Covidien plc develops, manufactures, and sells healthcare products for use in clinical and home settings worldwide. The stock currently has a dividend yield of 1.54%. The company has a P/E ratio of 25.7. Currently, there are 5 analysts who rate Covidien a buy, no analysts rate it a sell, and 12 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on COV - FREE

TheStreet Quant Ratings

rates Covidien as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, growth in earnings per share, increase in net income and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full

Covidien Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null